# A Study to Evaluate Ocrelizumab in Patients With Nephritis Due to Systemic Lupus Erythematosus (BELONG)

> **NCT00626197** · PHASE3 · TERMINATED · sponsor: **Genentech, Inc.** · enrollment: 381 (actual)

## Conditions studied

- Lupus Nephritis
- Systemic Lupus Erythematosus

## Interventions

- **DRUG:** Corticosteroids
- **DRUG:** Cyclophosphamide
- **DRUG:** Mycophenolate Mofetil
- **DRUG:** Ocrelizumab
- **DRUG:** Placebo
- **DRUG:** Azathioprine

## Key facts

- **NCT ID:** NCT00626197
- **Lead sponsor:** Genentech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-02-15
- **Primary completion:** 2009-10-19
- **Final completion:** 2013-10-28
- **Target enrollment:** 381 (ACTUAL)
- **Why stopped:** Study was terminated due to an imbalance of serious and opportunistic infections in the ocrelizumab treated patients versus the placebo arm.
- **Last updated:** 2020-12-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00626197

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00626197, "A Study to Evaluate Ocrelizumab in Patients With Nephritis Due to Systemic Lupus Erythematosus (BELONG)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00626197. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*